HealthTree Cure Hub is a patient data portal where patients can contribute data to accelerate multiple myeloma research. The results of these research projects are then published as abstracts at international conferences and and as manuscripts in medical peer-reviewed journals. To access HealthTree Cure Hub data for multiple myeloma research, go to healthtree.org/research and request a demo.

Pre-Print Publications

The primary aim of disseminating pre-publication research findings is to bring benefits to patients actively engaged in HealthTree Cure Hub. We intend to recognize and appreciate their valuable contributions and participation by granting them early access to potentially valuable information. However, it's important to be aware that the data, interpretations, and final conclusions are subject to change as the research projects expand in sample size and undergo the peer-reviewed publication process.

• IMS 2024 - Ocular complications are common in patients with multiple myeloma receiving dexamethasone:  Results of a cross-sectional patient survey

2024 Publications

• Blood 2024 - EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
• ASCO 2024 - Meeting Poster - Supplement use habits and perceptions in patients with plasma cell disorders.
• ASCO 2024 - Meeting Abstract - Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.
• ASCO 2024 - Meeting Abstract - Exploring gender-based decision-making differences among patients with relapsed/refractory multiple myeloma.
• ASCO 2024 - Meeting Abstract - The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma.
• ASCO 2024 - Meeting Abstract - Age-related differences in information-seeking behaviors of patients with multiple myeloma.
• ASCO 2024 - Meeting Abstract - Diagnosis disclosure patterns among patients with plasma cell disorders.
• ASCO 2024 - Meeting Abstract - The role of patient-driven education in decision-making for relapsed/refractory multiple myeloma.
• Fontiers in Health Services: Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group
• TNT 2024 - Meeting Poster -  Unraveling the Dynamics of Protein Secretion in Multiple Myeloma: A Comparative Study of Non-Secretory Patterns and Disease Evolution (As ASH 2023 Online Only Abstract)
• TNT 2024 - Meeting Poster - Cannabis and Cannabinoid Use and Perceptions in Patients with Plasma Cell Disorders: A National Healthtree Foundation for Multiple Myeloma Survey

2024 Research Posters

• TNT 2024 - Non-Secretory Protein Secretion
• ASCO 2024 - Supplement Use Habits and Perceptions in Patients with Plasma Cell Disorders
• Fostering collaborative care in MM- The impact of holistic education on decision-making with antibody and CAR-T cell platforms
• Diagnosis disclosure patterns among patients with plasma cell disorders
• The effect of care team-patient relationship on decision-making in relapsed-refractory multiple myeloma
• Exploring gender-based decision-making differences among patients with relapsed-refractory MM
• The role of patient-driven education in decision-making for relapse-refractory MM

2023 Publications

• ASH 2023 - Meeting Abstract: Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
• ASH 2023 - Meeting Poster: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
• ASH 2023 - Meeting Poster: Age-Based Comparison of Stem Cell Transplantation during the First Line of Therapy for Multiple Myeloma Patients
• ASH 2024 - Meeting Abstract: Age-Based Comparison of Dara-Rvd, Krd and Rvd Induction Therapies during the First Line of Therapy for Multiple Myeloma Patients
• AONN 2023 - Meeting Poster Abstract: Doctor-Patient Relationships and Patient Satisfaction in Multiple Myeloma: Implications of Shared Decision-Making and Racial Disparities
• IMS 2023 - Meeting Abstract: Association between dexamethasone exposure and visually significant cataracts in myeloma
• IMS 2023 - Meeting Abstract: Role of Education and Empowerment in Multiple Myeloma patients
• IMS 2023 - Meeting Abstract: Multiple myeloma patient perceptions of minimal residual disease testing
• IMS 2023 - Meeting Abstract: Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hub’s Study of Multiple Myeloma Patients
• AJH - Association between dexamethasone exposure and visually significant cataracts in multiple myeloma - Poster Presented at IMS 2023
• MSSE - Physical Activity and Patient-Reported Outcomes in Monoclonal Plasma Cell Disorders
• ASCO 2023 Meeting Abstract: Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients.
• ASCO 2023 Meeting Abstract: Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
• Complementary Therapies in Medicine: Integrative medicine in multiple myeloma and plasma cell disorders
• TCT 2023 Meeting Poster: Exploratory Analysis of Efficacy and Toxicity in CAR T-Cell Therapy for Multiple Myeloma Using Real-World Data
• TCT 2023 Meeting Poster: The Side Effect Prevalence and Severity of Multiple Myeloma Doublet Vs Triplet Induction Therapy: A Retrospective Comparison of Patients Older Than 68 Years.

2023 Research Posters

• AONN 2023 - Decision Making 1
• AONN 2023 - Decision Making 2
• IMS 2023 - Cataracts and Dex
• IMS 2023 - Role of Education and Empowerment
• IMS 2023 - Real-World Efficacy of CAR-T Cell Therapies
• ASH 2023 - Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing
• ASH 2023 - Age-Based Comparison of Stem Cell Transplantation during the First Line of Therapy for Multiple Myeloma Patients
• 2023 Patient Perspective on BCMA-Targeted Therapies

2022 Publications

• Blood Cancer Journal: Nutrition perceptions, needs and practices among patients with plasma cell disorders.
• Journal of Clinical Oncology: HealthTree Cure Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles and Accelerate Research in Multiple Myeloma
• AONN 2022 Meeting Poster Abstract: Impact of a HealthTree Myeloma Coach on Quality of Life for Multiple Myeloma Patients: A Pilot Study
• AONN 2022 Meeting Poster Abstract: What Are the Top African American Myeloma Patient Concerns at and Since Diagnosis?
• COMy 2022 Meeting Abstract: High-dose melphalan on multiple myeloma-related mutations, risk-level, and secondary disease burden 
• COMy 2022 Meeting Abstract: Prognostic implication of Del(13q) after exposure to pesticides in newly diagnosed multiple myeloma 
• ASCO 2022 Meeting Abstract: A patient perspective on cure in multiple myeloma: A survey of over 1,500 patients 
• ASCO 2022 Meeting Abstract: Early intervention for high-risk and low-risk of progression for patients with smoldering multiple myeloma. 
• ASCO 2022 Meeting Abstract: Geographic disparity between patients with multiple myeloma (non-Whites and Whites) 
• The Lancet Haematology: A survey on the patient perspective on cure in multiple myeloma
• Blood: Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study
• ASH 2022 Meeting Abstract: Physical Activity in Patients with Monoclonal Gammopathies – a Healthtree Cure Hub Study
• ASH 2022 Meeting Abstract: Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
• ASH 2022 Meeting Abstract: The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients
• ASH 2022 Meeting Abstract: A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy
• ASH 2022 Meeting Abstract: The Relationship between Therapeutic Pressure and Multiple Myeloma Risk Stratification: A 5 Year Real-World-Data Analysis
• ASH 2022 Meeting Abstract: What Are the Top Myeloma Patient Concerns at and Since Diagnosis?

2021 Publications

• AACR 2021 Meeting Abstract: Relationship of ABO blood groups and length of survival of multiple myeloma patients
• AACR 2021 Meeting Abstract: Comparison of multiple myeloma providers for Black Americans and Caucasian Americans
• ASCO 2021 Meeting Abstract: Patient-reported efficacy and toxicity in CAR T-cell therapy for multiple myeloma via internet-based platforms
• ASCO 2021 Meeting Abstract:  Tandem versus single autologous stem cell transplant: A patient-reported outcome.
• ASCO 2021 Meeting Abstract:  Patient-reported experience platform identifies discordance between guidelines and real-world practice: Maintenance therapy for high-risk multiple myeloma.
• ASCO 2021 Meeting Abstract:  Acute and chronic cancer-related distress among multiple myeloma patients during the COVID-19 pandemic.
• ASCO 2021 Meeting Abstract: Integrative medicine and plasma cell disorders.
• ASH 2021 Meeting Abstract: Utilizing HealthTree Cure Hub’s real-world data to assess treatment management of patients with multiple myeloma during the COVID-19 pandemic
• ASH 2021 Meeting Abstract:  Online patient-reported platform detects trend of increased COVID-19 risk and severity for multiple myeloma patients on active lenalidomide-based therapy
• ASH 2021 Meeting Abstract:  Multiple Myeloma, Clinical Characteristics, and Increased COVID-19 Risk Using Real-World Data

2020 Publications

• Dermatology and Therapy: Clinical characteristics of 18 patients with psoriasis and multiple myeloma identified through digital health crowdsourcing.
• AACR 2020 Meeting Abstract:  Telehealth use among multiple myeloma patients during the COVID-19 pandemic.
• ASCO 2020 Meeting Abstract: HealthTree Patient Portal mediated myeloma patient-reported vaccination and antibiotic use.
• ASCO 2020 Meeting Abstract: HealthTree Patient Portal mediated myeloma patient-reported diagnostic imaging and pathology testing.
• IMW 2020 Meeting Abstract: Providing Nutrition Guidance for Patients with Plasma Cell Disorders – A Missed Opportunity for Hematologists/Oncologists?
• AACR COVID-19 and Cancer 2020 Meeting Abstract:  Cancer-related distress among multiple myeloma patients during the COVID-19 pandemic.